http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-046782-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_31b90307b425208a563b3924c700fc04 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D263-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-501 |
| filingDate | 2004-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-046782-A1 |
| titleOfInvention | HALEROCICLY COMPOUNDS OF HALOGENATED BIARILO, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, METHODS FOR THEIR ELABORATION AND ITS USE AS MEDICATIONS. |
| abstract | Halogenated heterocyclic biaryl compounds used as anti-infective, anti-proliferative, anti-inflammatory and prokinetic agents. Claim 1: A compound having the formula (1) or a pharmaceutically acceptable salt, ester or prodrug of said compounds, wherein A is selected from the group consisting of: phenyl, pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl; B is selected from the group consisting of: phenyl, pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl; Het-CH2-R3 is selected from the group consisting of formulas (2), M is selected from the group consisting of: a) C1-6 alkyl, b) C2-6 alkenyl; and c) C2-6 alkynyl; wherein i) any of (a) - (c) is substituted with one or more portions selected from the group consisting of F, Cl, Br and I, and ii) any of (a) - (c), optionally , is additionally substituted with one or more R4 groups; X is selected from the group consisting of: a) -O-, b) -NR5-, c) -N (O) -, d) -N (OR5) -, e) - S (O) p-, f ) -NR5- N =, g) = N-NR5-, h) -ON =, i) = NO-, j) -N =, k) = N-, i) -NR5-NR5-, m) - NR5C (O) O-, n) -OC (O) NR5-, o) -NR5C (O) NR5-, p) -NR5C (NR5) NR5- and q) as shown in formula (3), L se selects from the group consisting of: a) C1-6 alkyl, b) C2-6 alkenyl, and c) C2-6 alkynyl; wherein any of (a) - (c), optionally, is substituted with one or more R4 groups; R1 at each occurrence, is independently selected from the group consisting of: a) F, b) Cl, c) Br, d) I, e) - CF3, f) -OR7, g) -CN, h) - NO2, i) -NR7R7, j) -C (O) R7, k) -C (O) OR7, i) -OC (O) R7, m) -C (O) NR7R7, n) -NR7C (O) R7, o) -OC (O) NR7R7, p) -NR7C (O) OR7, q) -NR7C (O) NR7R7, r) -C (S) R7, s) -C (S) OR7, t) - OC (S) R7, u) -C (S) NR7R7, v) -NR7C (S) R7, w) -OC (S) NR7R7, x) - NR7C (S) OR7, y) - NR7C (S) NR7R7 , z) -NR7C (NR7) R7, aa) -S (O) pR7, bb) -SO2NR7R7 and cc) R7; R2 at each occurrence, is independently selected from the group consisting of: a) F, b) Cl, c) Br, d) I, e) -CF3, f) -OR7, g) -CN, h) - NO2, i) -NR7R7, j) - C (O) R7, k) - C (O) OR7, i) -OC (O) R7, m) -C (O) NR7R7, n) -NR7C (O) R7, o) -OC (O) NR7R7, p) -NR7C (O) OR7, q) -NR7C (O) NR7R7, r) -C (S) R7, s) -C (S) OR7, t) - OC (S) R7, u) -C (S) NR7R7, v) -NR7C (S) R7, w) -OC (S) NR7R7, x) -NR7C (S) OR7, and) -NR7C (S) NR7R7 , z) -NR7C (NR7) R7, aa) -S (O) pR7, bb) -SO2NR7R7 and cc) R7; R3 is selected from the group consisting of: a) -OR7, b) -NR7R7, c) -C (O) R7, d) -C (O) OR7, e) -OC (O) R7, f) -C (O) NR7R7, g) -NR7C (O) R7, h) -OC (O) NR7R7, i) -NR7C (O) OR7, j) -NR7C (O) NR7R7, k) -C (S) R7, l) -C (S) OR7, m) - OC (S) R7, n) -C (S) NR7R7, o) -NR7C (S) R7, p) -OC (S) NR7R7, q) -NR7C ( S) OR7, r) -NR7C (S) NR7R7, s) -NR7C (NR7) NR7R7, t -S (O) pR7, u) -SO2NR7R7 and v) R7; R4, at each occurrence, is independently selected from the group consisting of: a) H, b) F, c) Cl, d) Br, e) I, f) = O g) = S, h) = NR5 , i) = NOR5, j) = N-NR5R5, k) -CF3, l) -OR5, m) -CN, n) -NO2, o) -NR5R5, p) -C (O) R5, q) - C (O) OR5, r) -OC (O) R5, s) -C (O) NR5R5, t) -NR5C (O) R5, u) -OC (O) NR5R5, v) -NR5C (O) OR5 , w) -NR5C (O) NR5R5, x) -C (S) R5, y) -C (S) OR5, z) - OC (S) R5, aa) -C (S) NR5R5, bb) -NR5C (S) R5, cc) -OC (S) NR5R5, dd) -NR5C (S) OR5, ee) -NR5C (S) NR5R5, ff) -NR5C (NR5) NR5R5, gg) -S (O) pR5, hh) R5; R5 at each occurrence, is independently selected from the group consisting of: a) H, b) C1-6 alkyl, c) C2-6 alkenyl, d) C2-6 alkynyl, e) -C (O) -alkyl C1-6, f) -C (O) -C2-6 alkenyl, g) -C (O) -C2-6 alkynyl, h) -C (O) O-C1-6 alkyl, i) -C (O ) C2-6 O-alkenyl and j) -C (O) C2-6 alkynyl; wherein any of (b) - (j) is optionally substituted with one more R6 groups; R6, at each occurrence, is independently selected from the group consisting of: a) F, b) Cl, c) Br, d) I, e) -CF3, f) -OH, g) -C 1-6 alkyl , h) -SH, i) -C1-6 alkyl, j) -CN, k) -NO2, l) -NH2, m) -N C1-6 alkyl, n) - N (C1-6 alkyl) 2, or ) -C (O) C1-6 alkyl, p) -C (O) C1-6 alkyl, q) -C (O) NH2, r) -C (O) NH C1-6 alkyl, s) -C (O ) N (C1-6 alkyl) 2, t) -NHC (O) C1-6 alkyl and u) -S (O) C1-6 alkyl; R7 at each occurrence, is independently selected from the group consisting of: a) H, b) C1-6 alkyl, c) C2-6 alkenyl, d) C2-6 alkynyl, e) saturated C3-14 carbocycle, unsaturated or aromatic, f) saturated, unsaturated or aromatic 3-14 membered heterocycle, comprising one or more heteroatoms selected from the group consisting of N, O and S, g) -C (O) -C 1-6 alkyl, h ) -C (O) -C2-6 alkenyl, i) -C (O) -C2-6 alkynyl, j) -C (O) -C3-14 saturated, unsaturated or aromatic carbocycle, k) -C (O) - 3-14 saturated, unsaturated or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of N, O and S, l) -C (O) O-C1-6 alkyl, m) -C (O ) C2-6 O-alkenyl, n) -C (O) C2-6 O-alkynyl, o) -C (O) C3-14 saturated, unsaturated or aromatic O-carbocycle and p) -C (O) O-heterocycle 3-14 saturated, unsaturated or aromatic members comprising one or more heteroatoms selected from the group consisting of N, O and S, wherein any of (b) - (p), in the form optional, it is substituted with one or more R8 groups; R8, at each occurrence, is independently selected from the group consisting of: a) F, b) Cl, c) Br, d) I, e) = O f) = S, g) = NR9, h) = NOR9, i) = N-NR9R9, j) -CF3, k) -OR9, l) -CN, m) -NO2, n) -NR9R9, or) -C (O) R9, p) -C (O) OR9, q) -OC (O) R9, r) -C (O) NR9R9, s) -NR9C (O) R9, t) - OC (O) NR9R9, u) -NR9C (O) OR9, v) - NR9C (O) NR9R9, w) -C (S) R9, x) -C (S) OR9, y) -OC (S) R9, z) -C (S) NR9R9, aa) -NR9C (S) R9 , bb) -OC (S) NR9R9, cc) -NR9C (S) OR9, dd) -NR9C (S) NR9R9, ee) -NR9C (NR9) R9, ff) -S (O) pR9, gg) -SO2NR9R9 , hh) R9; R9 at each occurrence, is independently selected from the group consisting of: a) H, b) C1-6 alkyl, c) C2-6 alkenyl, d) C2-6 alkynyl, e) saturated, unsaturated C3-14 carbocycle or aromatic, f) saturated, unsaturated or aromatic 3-14 membered heterocycle, comprising one or more heteroatoms selected from the group consisting of N, O and S, g) -C (O) -C 1-6 alkyl, h) -C (O) -C2-6 alkenyl, i) -C (O) -C2-6 alkynyl, j) -C (O) -C3-14 saturated, unsaturated or aromatic carbocycle, k) -C (O) - saturated, unsaturated or aromatic 3-14 membered heterocycle comprising one or more heteroatoms selected from the group consisting of N, O and S, 1) -C (O) O-C 1-6 alkyl, m) -C (O) C2-6 O-alkenyl, n) -C (O) C2-6 alkynyl, or) -C (O) C3-14 saturated, unsaturated or aromatic O-carbocycle and p) -C (O) O-heterocycle of 3-14 saturated, unsaturated or aromatic members comprising one or more heteroatoms selected from the group consisting of N, O and S, wherein any of b) -p), optionally nal, is substituted with one or more portions selected from the group consisting of: a) F, b) Cl, c) Br, d) I, e) -CF3, f) -OH, g) -C 1-6 alkyl, h) -SH, i) -C1-6 alkyl, j) -CN, k) -NO2, l) -NH2, m) -N C1-6 alkyl, n) N (C1-6 alkyl) 2, o) - C (O) C1-6 alkyl, p) - C (O) C1-6 alkyl, q) -C (O) NH2, r) -C (O) NH C1-6 alkyl, s) -C (O) N (C1-6 alkyl) 2, t) -NHC (O) C1-6 alkyl, u) -SO2NH2-, v) -SO2NH C1-6 alkyl, w) -SO2N (C1-6 alkyl) 2 and x) -S ( O) C1-6 palquil, m is 0, 1, 2, 3, or 4; n is 0, 1, 2, 3, or 4, and p, at each occurrence, is independently 0, 1 or 2. Claim 55: A method of synthesizing a pharmaceutically acceptable compound or salt thereof according to any one of claims 1 to 44. |
| priorityDate | 2003-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811 |
Total number of triples: 27.